参考文献/References:
[1]Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2]Jayson GC,Kohn EC,Kitchener HC,et al.Ovarian cancer[J].Lancet,2014,384(9951):1376-1388.
[3]Sundar S,Neal RD,Kehoe S.Diagnosis of ovarian cancer[J].BMJ,2015(351):h4443.
[4]Anastasiadou E,Jacob LS,Slack FJ.Non-coding RNA networks in cancer[J].Nat Rev Cancer,2018,18(1):5-18.
[5]Dalmay T,Edwards DR.MicroRNAs and the hallmarks of cancer[J].Onco gene,2006,25(46):6170-6175.
[6]Guttman M,Rinn JL.Modular regulatory principles of large non-coding RNAs[J].Nature,2012,482(7385):339-346.
[7]Memczak S,Jens M,Elefsinioti A,et al.Circular RNAs are a large class of animal RNAs with regulatory potency[J].Nature,2013,495(7441):333-338.
[8]Esteller M.Non-coding RNAs in human disease[J].Nat Rev Genet,2011,12(12):861-874.
[9]St Laurent G,Wahlestedt C,Kapranov P.The Landscape of long noncoding RNA classification[J].Trends Genet,2015,31(5):239-251.
[10]Dhahbi JM,Spindler SR,Atamna H,et al.Deep Sequencing of Serum Small RNAs Identifies Patterns of 5′tRNA Half and YRNA Fragment Expression Associated with Breast Cancer[J].Biomark Cancer,2014(6):37-47.
[11]Venkatesh T,Suresh PS,Tsutsumi R.Non-coding RNAs:Functions and applications in endocrine-related cancer[J].Mol Cell Endocrinol,2015(416):88-96.
[12]Braicu C,Catana C,Calin GA,et al.NCRNA combined therapy as future treatment option for cancer[J].Curr Pharm Des,2014,20(42):6565-6574.
[13]Hayes J,Peruzzi PP,Lawler S.MicroRNAs in cancer:biomarkers, functions and therapy[J].Trends Mol Med,2014,20(8):460-469.
[14]Chen Y,Fu LL,Wen X,et al.Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy[J].Apoptosis,2014,19(8):1177-1189.
[15]Bagnoli M,Canevari S,Califano D,et al.Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study[J].Lancet Oncol,2016,17(8):1137-1146.
[16]Cramer DW,Elias KM.A prognostically relevant miRNA signature for epithelial ovarian cancer[J].Lancet Oncol,2016,17(8):1032-1033.
[17]Mak CS,Yung MM,Hui LM,et al.MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis[J].Mol Cancer, 2017,16(1):11.
[18]Barbier J,Chen X,Sanchez G,et al.An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression[J].Cell Res,2018,28(5):556-571.
[19]Elias KM,Fendler W,Stawiski K,et al.Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer[J].Elife,2017(6):e28932.
[20]Shah JS,Gard GB,Yang J,et al.Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer[J].Gynecol Oncol,2018,148(1):181-188.
[21]Ulitsky I.Evolution to the rescue: using comparative genomics to understand long non-coding RNAs[J].Nat Rev Genet,2016,17(10):601-614.
[22]Mitra R,Chen X,Greenawalt EJ,et al.Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition[J].Nat Commun,2017,8(1):1604.
[23]Liang H,Yu T,Han Y,et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J].Mol Cancer,2018,17(1):119.
[24]Teschendorff AE,Lee SH,Jones A,et al.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer[J].Genome Med,2015(7):108.
[25]Chen Y,Du H,Bao L,et al.LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214[J].Cancer Biol Med,2018,15(3):238-250.
[26]Li N,Zhan X,Zhan X.The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes[J].Gynecol Oncol,2018,150(2):343-354.
[27]Bachmayr-Heyda A,Reiner AT,Auer K,et al.Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer,idiopathic lung fibrosis,and normal human tissues[J].Sci Rep,2015(5):8057.
[28]Ahmed I,Karedath T,Andrews SS,et al.Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma[J].Oncotarget,2016,7(24):36366-36381.
[29]Liu N,Zhang J,Zhang LY,et al.CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer[J].Eur Rev Med Pharmacol Sci,2018,22(12):3713-3718.
相似文献/References:
[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,31(05):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]沈云志,王毅军.miRNA及LncRNA在器官移植免疫排斥中作用的研究进展[J].医学信息,2019,32(02):43.[doi:10.3969/j.issn.1006-1959.2019.02.015]
SHEN Yun-zhi,WANG Yi-jun.Advances in the Role of miRNA and LncRNA in Immune Rejection of Organ Transplantation[J].Medical Information,2019,32(05):43.[doi:10.3969/j.issn.1006-1959.2019.02.015]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(05):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,32(05):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(05):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Medical Information,2019,32(05):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[8]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Medical Information,2019,32(05):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[9]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Medical Information,2020,33(05):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
[10]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Medical Information,2020,33(05):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]